Efficacy, safety and cost-effectiveness of 5-fluorouracil versus interferon α-2b as adjuvant therapy after surgery in ocular surface squamous neoplasia in a southern European tertiary hospital
International Ophthalmology · 2024
DOI: 10.1007/s10792-024-03105-w ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Ophthalmology, 2024. Verfasst von José Javier San Román Llorens und 5 weiteren Autor:innen. Beteiligte Einrichtung: University Hospital Fundación Jiménez Diaz, Avenida Reyes Católicos 2, 28040, Madrid, Spain. jose.sanroman@quironsalud.es. Hauptthemen laut MEDLINE: Conjunctival Neoplasms, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: To analyze the efficacy, safety and cost-effectiveness of adjuvant therapy with 5-fluorouracil (5-FU) compared to interferon α-2b (IFNα-2b) after surgery in ocular surface squamous neoplasia (OSSN). METHODS: Retrospective study that included patients diagnosed with OSSN, who underwent surgical excision followed by adjuvant therapy with IFN α-2b (Group A) or 5-FU (Group B), in a tertial referral hospital. Clinical data collected included: demographics, risk factors, appearance, size and location of the lesions, slit-lamp examination, anterior segment optical coherence tomography, iconography and histological classification of subtypes of OSSN. Costs derived from surgery and adjuvant therapy were noted. Resolution of the lesion, recurrences and adverse events were studied. Cost-effectiveness analysis was performed with the incremental cost-effectiveness index (CEI). RESULTS: 54 cases of 54 patients were included, with a mean age of 74.4 years (range 28-109). 30 were male (55.6%), and predominantly Caucasian (79.6%). The main risk factor was prolonged sun exposure (79.6%). Leukoplakic appearance (48.1%), location in bulbar conjunctiva (48.2%) and T3 (46.3%) stage were the most common clinical features. Histologically, the percentage of CIN I, CIN II, CIN III and SCC were 25.9%, 29.6%, 40.7% and 3.7%, respectively. Complete resolution was obtained in 74.1% and tolerance was overall positive. The cost was significantly higher for IFNα (1025€ ± 130.68€) compared to 5-FU (165.57€ ± 45.85 €) (p 0.001). The CEI was - 247.14€. CONCLUSIONS: Both 5-FU and IFN α-2b are effective and present a good security profile as adjuvant therapies after surgery in OSSN. Although presenting slightly more ocular complications, 5-FU can be considered more cost-effective than IFN α-2b.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University Hospital Fundación Jiménez Diaz, Avenida Reyes Católicos 2, 28040, Madrid, Spain. jose.sanroman@quironsalud.es.
- Ruber Juan Bravo Hospital, Madrid, Spain. jose.sanroman@quironsalud.es.
- University Hospital Fundación Jiménez Diaz, Avenida Reyes Católicos 2, 28040, Madrid, Spain.
- Ruber Juan Bravo Hospital, Madrid, Spain.
Zitieren
APA
San Román Llorens, J. J., Fernández-Gurria, M., Artaechevarria Artieda, J., Alejandre Alba, N., García Sandoval, B., & Jiménez-Alfaro Morote, I. (2024). Efficacy, safety and cost-effectiveness of 5-fluorouracil versus interferon α-2b as adjuvant therapy after surgery in ocular surface squamous neoplasia in a southern European tertiary hospital. International Ophthalmology. https://doi.org/10.1007/s10792-024-03105-w
Vancouver
San Román Llorens JJ, Fernández-Gurria M, Artaechevarria Artieda J, Alejandre Alba N, García Sandoval B, Jiménez-Alfaro Morote I. Efficacy, safety and cost-effectiveness of 5-fluorouracil versus interferon α-2b as adjuvant therapy after surgery in ocular surface squamous neoplasia in a southern European tertiary hospital. International Ophthalmology. 2024. doi:10.1007/s10792-024-03105-w
BibTeX
@article{SanRomnLlorens2024,
author = {San Román Llorens, José Javier and Fernández-Gurria, Marta and Artaechevarria Artieda, June and Alejandre Alba, Nicolas and García Sandoval, Blanca and Jiménez-Alfaro Morote, Ignacio},
title = {Efficacy, safety and cost-effectiveness of 5-fluorouracil versus interferon α-2b as adjuvant therapy after surgery in ocular surface squamous neoplasia in a southern European tertiary hospital},
journal = {International Ophthalmology},
year = {2024},
doi = {10.1007/s10792-024-03105-w}
}
EUVIMED